February 17, 2016 (Update) - On February 8, 2016, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced results from OPuS-2 (Oral ProphylaxiS-2), a clinical trial ofavoralstat administered three times daily as a liquid-filled soft gel formulation for the prophylactic treatment of hereditary angioedema (HAE) attacks.

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) declined to as low as $1.63 per share on February 12, 2016.

October 13, 2015 (Shareholders Foundation) - An investigation on behalf of investors of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares over potential securities laws violations by BioCryst Pharmaceuticals and certain of its directors and officers in connection certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) concerning whether a series of statements by BioCryst Pharmaceuticals regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

BioCryst Pharmaceuticals, Inc. reported that its annual Total Revenue declined from $17.33 million in 2013 to $13.61 million in 2014 and that its Net Loss increased from $30.11 million to $45.19 million

On October 8, 2015, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced that the randomized, placebo-controlled, Phase 1 clinical trial of orally-administeredBCX7353 in healthy volunteers successfully met all of its objectives. In a separate announcement BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX announced the completion of patient enrollment in OPuS-2: a Clinical Trial of Avoralstat in Patients With HAE

Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) declined from $16.39 per share to as low as $8.01 per share on October 8, 2015.